$PMNT
Perfect Moment Ltd.

2024 Q4 Form 10-Q Financial Statement

#000149315224045852 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $3.833M $5.888M
YoY Change -34.9% 134.49%
Cost Of Revenue $1.762M $3.223M
YoY Change -45.33% 90.04%
Gross Profit $2.071M $2.665M
YoY Change -22.29% 226.99%
Gross Profit Margin 54.03% 45.26%
Selling, General & Admin $3.923M $2.812M
YoY Change 39.51% -1.02%
% of Gross Profit 189.43% 105.52%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $106.0K $158.0K
YoY Change -32.91% 25.4%
% of Gross Profit 5.12% 5.93%
Operating Expenses $4.628M $2.968M
YoY Change 55.93% 0.07%
Operating Profit -$2.557M -$303.0K
YoY Change 743.89% -85.91%
Interest Expense $188.0K -$1.208M
YoY Change -115.56% -23.5%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.511M
YoY Change -59.49%
Income Tax
% Of Pretax Income
Net Earnings -$2.744M -$1.511M
YoY Change 81.6% -59.49%
Net Earnings / Revenue -71.59% -25.66%
Basic Earnings Per Share -$0.17 -$0.29
Diluted Earnings Per Share -$0.17 -$0.10
COMMON SHARES
Basic Shares Outstanding 16.01M shares 15.71M shares 5.187M shares
Diluted Shares Outstanding 15.78M shares 5.187M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $981.0K
YoY Change
Cash & Equivalents $725.0K $981.0K
Short-Term Investments
Other Short-Term Assets $3.961M
YoY Change
Inventory $5.331M $3.999M
Prepaid Expenses
Receivables $2.458M $2.339M
Other Receivables $308.0K
Total Short-Term Assets $12.72M $11.59M
YoY Change 9.8%
LONG-TERM ASSETS
Property, Plant & Equipment $413.0K $782.0K
YoY Change -47.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $41.00K $163.0K
YoY Change -74.85%
Total Long-Term Assets $551.0K $955.0K
YoY Change -42.3%
TOTAL ASSETS
Total Short-Term Assets $12.72M $11.59M
Total Long-Term Assets $551.0K $955.0K
Total Assets $13.28M $12.54M
YoY Change 5.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.144M $2.761M
YoY Change 50.09%
Accrued Expenses $2.338M $1.918M
YoY Change 21.9%
Deferred Revenue
YoY Change
Short-Term Debt $1.782M $11.52M
YoY Change -84.53%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.58M $18.30M
YoY Change -42.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $29.00K
YoY Change
Total Long-Term Liabilities $16.00K $29.00K
YoY Change -44.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.58M $18.30M
Total Long-Term Liabilities $16.00K $29.00K
Total Liabilities $10.60M $18.32M
YoY Change -42.17%
SHAREHOLDERS EQUITY
Retained Earnings -$55.11M
YoY Change
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.679M -$5.781M
YoY Change
Total Liabilities & Shareholders Equity $13.28M $12.54M
YoY Change 5.84%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$2.744M -$1.511M
YoY Change 81.6% -59.49%
Depreciation, Depletion And Amortization $106.0K $158.0K
YoY Change -32.91% 25.4%
Cash From Operating Activities -$1.047M
YoY Change -71.95%
INVESTING ACTIVITIES
Capital Expenditures $53.00K
YoY Change -15.87%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$53.00K
YoY Change -15.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.361M
YoY Change -65.53%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 784.0K
YoY Change -88.19%
NET CHANGE
Cash From Operating Activities -1.047M
Cash From Investing Activities -53.00K
Cash From Financing Activities 784.0K
Net Change In Cash -316.0K
YoY Change -111.12%
FREE CASH FLOW
Cash From Operating Activities -$1.047M
Capital Expenditures $53.00K
Free Cash Flow -$1.100M
YoY Change -71.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1035000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
143000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1762000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
2071000 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3923000 usd
CY2024Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
705000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
4628000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2557000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2744000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
21000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2723000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Entity Registrant Name
EntityRegistrantName
Perfect Moment Ltd.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-1437114
dei Entity Address Address Line1
EntityAddressAddressLine1
244 5th Ave Ste 1219
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
47000 usd
CY2024Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
692000 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1584000 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2697000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001849221
CY2024Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
usd
CY2024Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
usd
CY2024Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
us-gaap Inventory Write Down
InventoryWriteDown
usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
usd
PMNT Accrued Interest
AccruedInterest
usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
usd
PMNT Repayment Of Trade Finance Facilities Net
RepaymentOfTradeFinanceFacilitiesNet
usd
us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
usd
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
PMNT Fair Value Of Unamortized Stockbased Marketing And Other Services
FairValueOfUnamortizedStockbasedMarketingAndOtherServices
usd
PMNT Recognition Of Debt Discount On Shortterm Borrowings
RecognitionOfDebtDiscountOnShorttermBorrowings
usd
PMNT Recognition Of Operating Lease Right Of Use Assets And Lease Obligations
RecognitionOfOperatingLeaseRightOfUseAssetsAndLeaseObligations
usd
CY2024Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
shares
PMNT Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q3 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
usd
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41930
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10001
dei City Area Code
CityAreaCode
315
dei Local Phone Number
LocalPhoneNumber
615-6156
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001
dei Trading Symbol
TradingSymbol
PMNT
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16012889 shares
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
725000 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7910000 usd
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1825000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2458000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
5331000 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
2230000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2385000 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
742000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
12724000 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
11917000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
413000 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
502000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
97000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41000 usd
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
551000 usd
CY2024Q3 us-gaap Assets
Assets
13275000 usd
CY2024Q1 us-gaap Assets
Assets
12609000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4144000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2338000 usd
CY2024Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
906000 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
811000 usd
CY2024Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
1782000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
82000 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
101000 usd
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1328000 usd
CY2024Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
420000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10580000 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4802000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16000 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44000 usd
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
16000 usd
CY2024Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
44000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
10596000 usd
CY2024Q1 us-gaap Liabilities
Liabilities
4846000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15962889 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15962889 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15653449 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15653449 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
57865000 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
56824000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-78000 usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-85000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55109000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48977000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2679000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
7763000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13275000 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12609000 usd
CY2024Q3 us-gaap Revenues
Revenues
3833000 usd
CY2023Q3 us-gaap Revenues
Revenues
5888000 usd
us-gaap Revenues
Revenues
4808000 usd
us-gaap Revenues
Revenues
6876000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2609000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2378000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3115000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
3279000 usd
us-gaap Gross Profit
GrossProfit
2430000 usd
us-gaap Gross Profit
GrossProfit
3761000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2693000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7223000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5176000 usd
CY2023Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
888000 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1158000 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1597000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3581000 usd
us-gaap Operating Expenses
OperatingExpenses
8381000 usd
us-gaap Operating Expenses
OperatingExpenses
6773000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-302000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5951000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3012000 usd
CY2024Q3 us-gaap Interest Expense
InterestExpense
188000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
392000 usd
us-gaap Interest Expense
InterestExpense
194000 usd
us-gaap Interest Expense
InterestExpense
766000 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1000 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-817000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
13000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-406000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1511000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6132000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4184000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
739000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
351000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-772000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6125000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3833000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15781264 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15781264 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5186555 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5186555 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15717356 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15717356 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5082805 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5082805 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-6374000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
4000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1361000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
739000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1511000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-5781000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
4731000 usd
CY2024Q3 PMNT Stock Issued During Period Value Fair Value Of Shares Issued For Services
StockIssuedDuringPeriodValueFairValueOfSharesIssuedForServices
329000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
127000 usd
CY2024Q3 PMNT Stock Issued During Period Value Stock Compensation Expense For Employee Vested Options
StockIssuedDuringPeriodValueStockCompensationExpenseForEmployeeVestedOptions
215000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
21000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2744000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2679000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4141000 usd
PMNT Stock Issued During Period Value Stock Compensation Expense For Employee Vested Options
StockIssuedDuringPeriodValueStockCompensationExpenseForEmployeeVestedOptions
14000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2179000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
351000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4184000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-5781000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
7763000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
7763000 usd
PMNT Stock Issued During Period Value Fair Value Of Shares Issued For Services
StockIssuedDuringPeriodValueFairValueOfSharesIssuedForServices
329000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
204000 usd
PMNT Stock Issued During Period Value Stock Compensation Expense For Employee Vested Options
StockIssuedDuringPeriodValueStockCompensationExpenseForEmployeeVestedOptions
508000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6132000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2679000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2679000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6132000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4184000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
217000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
299000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
30000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
145000 usd
us-gaap Inventory Write Down
InventoryWriteDown
-290000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-327000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
712000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
14000 usd
PMNT Amortization Of Stock Based Marketing And Other Services
AmortizationOfStockBasedMarketingAndOtherServices
111000 usd
PMNT Amortization Of Stock Based Marketing And Other Services
AmortizationOfStockBasedMarketingAndOtherServices
185000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
181000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
348000 usd
PMNT Accrued Interest
AccruedInterest
400000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1435000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1399000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2811000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1769000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1425000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-122000 usd
PMNT Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-46000 usd
PMNT Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-109000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-46000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-112000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2559000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1469000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-359000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
305000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
908000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1891000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7734000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1850000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
102000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
82000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-102000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-82000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
125000 usd
PMNT Proceeds From Trade Finance Facilities Net
ProceedsFromTradeFinanceFacilitiesNet
906000 usd
PMNT Proceeds From Trade Finance Facilities Net
ProceedsFromTradeFinanceFacilitiesNet
847000 usd
PMNT Repayment Of Trade Finance Facilities Net
RepaymentOfTradeFinanceFacilitiesNet
875000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2179000 usd
us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
2000000 usd
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
399000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2507000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2026000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-31000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-216000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5360000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-122000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7910000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4712000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2550000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4590000 usd
us-gaap Interest Paid Net
InterestPaidNet
178000 usd
PMNT Fair Value Of Unamortized Stockbased Marketing And Other Services
FairValueOfUnamortizedStockbasedMarketingAndOtherServices
218000 usd
PMNT Recognition Of Debt Discount On Shortterm Borrowings
RecognitionOfDebtDiscountOnShorttermBorrowings
992000 usd
PMNT Recognition Of Operating Lease Right Of Use Assets And Lease Obligations
RecognitionOfOperatingLeaseRightOfUseAssetsAndLeaseObligations
107000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_806_eus-gaap--NatureOfOperations_zXoSpZJdvqza" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1. <span id="xdx_82C_zZOK7p53ujK6">NATURE OF OPERATIONS AND BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nature of operations</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Perfect Moment Ltd., a Delaware corporation (“Perfect Moment” or “PML” and, together with its subsidiaries unless the context otherwise requires, the “Company”), is an owner and operator of a luxury fashion brand that offers ski, swim, and activewear collections under the brand name Perfect Moment. The Company’s collections are sold directly to customers through e-commerce, sales to wholesale accounts and through other sales partnerships.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of presentation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required for complete consolidated financial statements. In the opinion of our management, these condensed consolidated financial statements contain all normal recurring adjustments considered necessary for a fair presentation of the Company’s financial position at September 30, 2024, results of operations for the three and six months ended September 30, 2024 and 2023, consolidated statements of shareholders’ equity for the three and six months ended September 30, 2024 and 2023, and cash flows for the six months ended September 30, 2024 and 2023. The Company’s results for the three and six months ended September 30, 2024 are not necessarily indicative of the results expected for the full year. You should read these statements in conjunction with our audited consolidated financial statements and management’s discussion and analysis and results of operations included in our Annual Report on Form 10-K (the “Form 10-K”) for the fiscal year ended March 31, 2024. The terms “fiscal 2025” and “fiscal 2024” refer to the Company’s fiscal year ending March 31, 2025 and fiscal year ended March 31, 2024, respectively. The figures in the notes to the financials are presented in thousands, therefore the 000’s are removed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Principles of consolidation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These unaudited condensed consolidated financial statements include the accounts of Perfect Moment Ltd. and its wholly owned subsidiaries; Perfect Moment Asia Limited (“PMA”), Perfect Moment (UK) Limited (“PMUK”), Perfect Moment USA, Inc., (“PMUSA”) and Perfect Moment TM Sarl. These unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments which are, in the opinion of management, necessary for the fair statement of the financial information for the interim periods presented. All intercompany balances and transactions have been eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Net Income Loss
NetIncomeLoss
-6132000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7734000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55109000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84F_eus-gaap--UseOfEstimates_zovLnLkr1IQh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments in applying the Company’s accounting policies that affect the reported amounts and disclosures made in the condensed consolidated financial statements and accompanying notes. Management continually evaluates the estimates and judgments it uses. These estimates and judgments have been applied in a manner consistent with prior periods and there are no known trends, commitments, events or uncertainties that management believe will materially affect the methodology or assumptions utilized in making these estimates and judgments in these financial statements. Significant estimates inherent in the preparation of the condensed consolidated financial statements include reserves for uncollectible accounts receivables, realizability of inventory; customer returns; useful lives and impairments of long-lived tangible and intangible assets; realization of deferred tax assets and related uncertain tax positions; and the valuation of stock-based compensation awards. Actual results may differ from these judgements and estimates under different assumptions or conditions and any such differences may be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Inventory Adjustments
InventoryAdjustments
156000 usd
CY2024Q1 us-gaap Inventory Adjustments
InventoryAdjustments
346000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3833000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3864000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4808000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4852000 usd
CY2024Q3 us-gaap Revenues
Revenues
3833000 usd
CY2023Q3 us-gaap Revenues
Revenues
5888000 usd
us-gaap Revenues
Revenues
4808000 usd
us-gaap Revenues
Revenues
6876000 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
570000 usd
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
558000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2458000 usd
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1035000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2024Q3 us-gaap Revenues
Revenues
3833000 usd
CY2023Q3 us-gaap Revenues
Revenues
5888000 usd
us-gaap Revenues
Revenues
4808000 usd
us-gaap Revenues
Revenues
6876000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zGO3Ep6JUsQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Customer concentration</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended September 30, 2024, we had one major customer, which accounted for approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--OneMajorCustomerMember_zR6wTQdQljma" title="Concentration risk percentage">15</span>% or $<span id="xdx_90E_eus-gaap--Revenues_pn3n3_c20240701__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--OneMajorCustomerMember_zCvjnbgm0sa5" title="Revenues">580</span> of total revenue. For the six months ended September 30, 2024, we had two major customers, which accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoMajorCustomerMember_zJipzul92Qxk" title="Concentration risk percentage">23</span>% or $<span id="xdx_906_eus-gaap--Revenues_pn3n3_c20240401__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoMajorCustomerMember_zG7y0Fkled68" title="Revenues">1,089</span> of total revenue. The related accounts receivable balance for these customers was $<span id="xdx_903_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zEueLhLRZ7T3" title="Accounts receivable">1,027</span> as of September 30, 2024, and $<span id="xdx_907_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zBitkzGBwlV7" title="Accounts receivable">71</span> as of March 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three and six months ended September 30, 2023, we had two major customers, which accounted for approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoMajorCustomerMember_zBixvUTS76rb" title="Concentration risk percentage">47</span>% or $<span id="xdx_90A_eus-gaap--Revenues_pn3n3_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoMajorCustomerMember_zAWVQKwvGtPd" title="Revenues">2,786</span> of total revenue and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoMajorCustomerMember_zqYCfzS5A9Ge" title="Concentration risk percentage">40</span>% or $<span id="xdx_908_eus-gaap--Revenues_pn3n3_c20230401__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoMajorCustomerMember_zFAGAVS05fSi" title="Revenues">2,786</span> of total revenue, respectively. The related accounts receivable balance for these customers was approximately $<span id="xdx_900_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zd4YeOLxXZJ3" title="Accounts receivable">760</span> as of September 30, 2023, and $<span id="xdx_90E_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zJOr4YNnBsye" title="Accounts receivable">41</span> as of March 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2088250 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9056416 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_847_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zR3rNrNAHbb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reclassifications</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has reclassified certain costs totaling $<span id="xdx_90B_eus-gaap--CostOfRevenue_pn3n3_c20230701__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zbndPpjpocc6" title="Cost of sales">614</span> and $<span id="xdx_902_eus-gaap--CostOfRevenue_pn3n3_c20230401__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_z5T7VuCv4y5" title="Cost of sales">991</span> previously classified as cost of sales for the three and six months ended September 30, 2023, respectively, to SG&amp;A expenses to conform to the current year presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
725000 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7910000 usd
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1825000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2550000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7910000 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4829000 usd
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2680000 usd
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
720000 usd
CY2024Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
721000 usd
CY2024Q3 us-gaap Other Inventory In Transit
OtherInventoryInTransit
684000 usd
CY2024Q1 us-gaap Other Inventory In Transit
OtherInventoryInTransit
14000 usd
CY2024Q3 PMNT Inventory Finished Goods On Consignment
InventoryFinishedGoodsOnConsignment
201000 usd
CY2024Q1 PMNT Inventory Finished Goods On Consignment
InventoryFinishedGoodsOnConsignment
205000 usd
CY2024Q3 us-gaap Inventory Gross
InventoryGross
6434000 usd
CY2024Q1 us-gaap Inventory Gross
InventoryGross
3620000 usd
CY2024Q3 us-gaap Inventory Lifo Reserve
InventoryLIFOReserve
1103000 usd
CY2024Q1 us-gaap Inventory Lifo Reserve
InventoryLIFOReserve
1390000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
5331000 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
2230000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2495000 usd
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2270000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2082000 usd
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1768000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
413000 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
502000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
106000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
162000 usd
us-gaap Depreciation
Depreciation
211000 usd
us-gaap Depreciation
Depreciation
301000 usd
CY2024Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
906000 usd
CY2024Q3 us-gaap Line Of Credit Facility Capacity Available For Trade Purchases
LineOfCreditFacilityCapacityAvailableForTradePurchases
2700000 usd
CY2024Q1 us-gaap Line Of Credit Facility Capacity Available For Trade Purchases
LineOfCreditFacilityCapacityAvailableForTradePurchases
5000000 usd
CY2024Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.033 pure
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
906000 usd
CY2024 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 usd
CY2024Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1941000 usd
CY2024Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
0 usd
CY2024Q3 PMNT Credit And Trade Loans
CreditAndTradeLoans
2845000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
1825000 usd
us-gaap Line Of Credit Assumed1
LineOfCreditAssumed1
2000000 usd
us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
2000000 usd
CY2024Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
2993000 usd
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
2593000 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
811000 usd
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
1782000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
225000 shares
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
801000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
29199 shares
PMNT Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted
50000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
29199 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
204000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
225000 shares
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
647000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.10
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1108356 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.42
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y5M12D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
595000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
688194 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.15
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1796550 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.94
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y1M9D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
177000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
610996 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.01
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
177000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
417237 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.06
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
177000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
508000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14000 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2652000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
177000 usd
CY2024Q3 us-gaap Cash
Cash
2550000 usd
CY2024Q1 us-gaap Cash
Cash
7910000 usd
CY2024Q3 us-gaap Cash
Cash
2550000 usd
CY2024Q1 us-gaap Cash
Cash
7910000 usd
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q3 us-gaap Purchase Obligation
PurchaseObligation
3026000 usd
CY2023Q3 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
112000 usd
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
237000 usd
CY2024Q3 PMNT Board Fees
BoardFees
118000 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001493152-24-045852-index-headers.html Edgar Link pending
0001493152-24-045852-index.html Edgar Link pending
0001493152-24-045852.txt Edgar Link pending
0001493152-24-045852-xbrl.zip Edgar Link pending
ex10-3.htm Edgar Link pending
ex10-3_001.jpg Edgar Link pending
ex10-3_002.jpg Edgar Link pending
ex10-3_003.jpg Edgar Link pending
ex10-3_004.jpg Edgar Link pending
ex10-3_005.jpg Edgar Link pending
ex10-3_006.jpg Edgar Link pending
ex10-3_007.jpg Edgar Link pending
ex10-3_008.jpg Edgar Link pending
ex10-3_009.jpg Edgar Link pending
ex10-3_010.jpg Edgar Link pending
ex10-3_011.jpg Edgar Link pending
ex10-3_012.jpg Edgar Link pending
ex10-3_013.jpg Edgar Link pending
ex10-3_014.jpg Edgar Link pending
ex10-3_015.jpg Edgar Link pending
ex10-3_016.jpg Edgar Link pending
ex10-3_017.jpg Edgar Link pending
ex10-3_018.jpg Edgar Link pending
ex10-3_019.jpg Edgar Link pending
ex10-3_020.jpg Edgar Link pending
ex10-3_021.jpg Edgar Link pending
ex10-3_022.jpg Edgar Link pending
ex10-3_023.jpg Edgar Link pending
ex10-3_024.jpg Edgar Link pending
ex10-4.htm Edgar Link pending
ex10-4_001.jpg Edgar Link pending
ex10-4_002.jpg Edgar Link pending
ex10-4_003.jpg Edgar Link pending
ex10-4_004.jpg Edgar Link pending
ex10-4_005.jpg Edgar Link pending
ex10-4_006.jpg Edgar Link pending
ex10-4_007.jpg Edgar Link pending
ex10-4_008.jpg Edgar Link pending
ex10-4_009.jpg Edgar Link pending
ex10-4_010.jpg Edgar Link pending
ex10-4_011.jpg Edgar Link pending
ex10-4_012.jpg Edgar Link pending
ex10-4_013.jpg Edgar Link pending
ex10-4_014.jpg Edgar Link pending
ex10-4_015.jpg Edgar Link pending
ex10-4_016.jpg Edgar Link pending
ex10-4_017.jpg Edgar Link pending
ex10-4_018.jpg Edgar Link pending
ex10-4_019.jpg Edgar Link pending
ex10-4_020.jpg Edgar Link pending
ex10-4_021.jpg Edgar Link pending
ex10-4_022.jpg Edgar Link pending
ex10-4_023.jpg Edgar Link pending
ex10-4_024.jpg Edgar Link pending
ex10-4_025.jpg Edgar Link pending
ex10-4_026.jpg Edgar Link pending
ex10-4_027.jpg Edgar Link pending
ex10-4_028.jpg Edgar Link pending
ex10-4_029.jpg Edgar Link pending
ex10-4_030.jpg Edgar Link pending
ex10-4_031.jpg Edgar Link pending
ex10-4_032.jpg Edgar Link pending
ex10-4_033.jpg Edgar Link pending
ex10-4_034.jpg Edgar Link pending
ex10-4_035.jpg Edgar Link pending
ex10-4_036.jpg Edgar Link pending
ex10-5.htm Edgar Link pending
ex10-5_001.jpg Edgar Link pending
ex10-5_002.jpg Edgar Link pending
ex10-5_003.jpg Edgar Link pending
ex10-5_004.jpg Edgar Link pending
ex10-5_005.jpg Edgar Link pending
ex10-5_006.jpg Edgar Link pending
ex10-5_007.jpg Edgar Link pending
ex10-5_008.jpg Edgar Link pending
ex10-5_009.jpg Edgar Link pending
ex10-5_010.jpg Edgar Link pending
ex10-5_011.jpg Edgar Link pending
ex10-5_012.jpg Edgar Link pending
ex10-5_013.jpg Edgar Link pending
ex10-5_014.jpg Edgar Link pending
ex10-5_015.jpg Edgar Link pending
ex10-5_016.jpg Edgar Link pending
ex10-5_017.jpg Edgar Link pending
ex10-5_018.jpg Edgar Link pending
ex10-5_019.jpg Edgar Link pending
ex10-5_020.jpg Edgar Link pending
ex10-5_021.jpg Edgar Link pending
ex10-5_022.jpg Edgar Link pending
ex10-5_023.jpg Edgar Link pending
ex10-5_024.jpg Edgar Link pending
ex10-5_025.jpg Edgar Link pending
ex10-5_026.jpg Edgar Link pending
ex10-5_027.jpg Edgar Link pending
ex10-5_028.jpg Edgar Link pending
ex10-5_029.jpg Edgar Link pending
ex10-5_030.jpg Edgar Link pending
ex10-5_031.jpg Edgar Link pending
ex10-5_032.jpg Edgar Link pending
ex10-5_033.jpg Edgar Link pending
ex10-5_034.jpg Edgar Link pending
ex10-5_035.jpg Edgar Link pending
ex10-5_036.jpg Edgar Link pending
ex10-5_037.jpg Edgar Link pending
ex10-5_038.jpg Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
pmnt-20240930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
pmnt-20240930_cal.xml Edgar Link unprocessable
pmnt-20240930_def.xml Edgar Link unprocessable
pmnt-20240930_lab.xml Edgar Link unprocessable
pmnt-20240930_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable